Celldex Therapeutics (CLDX) Projected to Release Quarterly Earnings on Thursday

Celldex Therapeutics (NASDAQ:CLDX) will likely be announcing its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect Celldex Therapeutics to post earnings of ($1.06) per share and revenue of $0.7350 million for the quarter. Individuals may visit the the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Monday, August 10, 2026 at 4:00 PM ET.

Celldex Therapeutics (NASDAQ:CLDX) last released its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.15) by ($0.03). The company had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.80 million. On average, analysts expect Celldex Therapeutics to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Celldex Therapeutics Stock Performance

Celldex Therapeutics stock opened at $39.05 on Wednesday. The stock’s 50 day simple moving average is $34.60 and its two-hundred day simple moving average is $31.24. The stock has a market cap of $3.07 billion, a price-to-earnings ratio of -9.17 and a beta of 0.87. Celldex Therapeutics has a fifty-two week low of $19.72 and a fifty-two week high of $40.30.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. Morgan Stanley lowered their target price on Celldex Therapeutics from $44.00 to $40.00 and set an “overweight” rating for the company in a research note on Wednesday, July 22nd. Barclays upped their price target on Celldex Therapeutics from $45.00 to $48.00 and gave the stock an “overweight” rating in a research note on Friday, May 8th. Canaccord Genuity Group decreased their price objective on Celldex Therapeutics from $62.00 to $60.00 and set a “buy” rating for the company in a report on Wednesday, July 22nd. UBS Group raised their price objective on Celldex Therapeutics from $38.00 to $45.00 and gave the company a “buy” rating in a research report on Wednesday, June 10th. Finally, Cantor Fitzgerald dropped their target price on shares of Celldex Therapeutics from $67.00 to $61.00 and set an “overweight” rating on the stock in a report on Wednesday, July 22nd. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Celldex Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $54.62.

Hedge Funds Weigh In On Celldex Therapeutics

Large investors have recently made changes to their positions in the business. Wilmington Savings Fund Society FSB purchased a new stake in shares of Celldex Therapeutics in the 3rd quarter worth approximately $42,000. Russell Investments Group Ltd. boosted its holdings in Celldex Therapeutics by 27.6% in the second quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company’s stock worth $47,000 after acquiring an additional 501 shares in the last quarter. Quantbot Technologies LP bought a new stake in Celldex Therapeutics in the third quarter worth $63,000. Kestra Advisory Services LLC purchased a new stake in shares of Celldex Therapeutics in the fourth quarter worth $98,000. Finally, Advisory Services Network LLC purchased a new stake in shares of Celldex Therapeutics in the third quarter worth $139,000.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.